middle.news
Clinuvel Advances with 4% Revenue Rise Amid Strategic Expansion and Clinical Progress
10:12am on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
Clinuvel Advances with 4% Revenue Rise Amid Strategic Expansion and Clinical Progress
10:12am on Thursday 26th of February, 2026 AEDT
Key Points
4% revenue growth driven by SCENESSE® sales in Europe and stable US demand
26% decline in profit after tax due to 22% rise in expenses for R&D and expansion
Cash reserves increased 4% to A$233 million, maintaining 21 years debt-free
Advancement of vitiligo clinical trials and expansion of Singapore RD&I Centre
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CLINUVEL PHARMACEUTICALS (ASX:CUV)
OPEN ARTICLE